Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
NCT04355793
·
clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class
Conditions
COVID-19
Interventions
DRUG:
Ruxolitinib
Sponsor
Incyte Corporation